|
"hsu chih hung"的相關文件
顯示項目 106-115 / 174 (共18頁)
<< < 6 7 8 9 10 11 12 13 14 15 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2009 |
The Aurora Kinase Inhibitor Ve-465 Has Anticancer Effects in Pre-Clinical Studies of Human Hepatocellular Carcinoma
|
許輝吉; 徐志宏; 葉培彥; 黃繼瑩; 郭頌鑫; 許駿; 胡賦強; 鄭永銘; 鄭安理; HSU, HEY-CHI; HSU, CHIH-HUNG; YEH, PEI-YEN; HUANG, CHI-YING; KUO, SUNG-HSIN; HSU, CHIUN; HU, FU-CHANG; JENG, YUNG-MING; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Bevacizumab (B) and Erlotinib (E) in Combination for Asian Patients (Pts) with Advanced/Metastatic Hepatocellular Carcinoma ( Hcc): An Interim Safety Report
|
徐志宏; 邱宗傑; 許駿; 鄭安理; HSU, CHIH-HUNG; CHIOU, TZEON-JYE; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Sorafenib in Combination with Tegafur/Uracil (Uft) for Asian Patients with Advanced Hepatocellular Carcinoma (Hcc)
|
沈盈君; 許駿; 徐志宏; 林宗哲; 陳培哲; 邵幼雲; 丁雅慧; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; HSU, CHIH-HUNG; LIN, ZONG-ZHE; CHEN, PEI-JER; SHAO, YU-YUN; DING, YEA-HUI; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Trial of Thalidomide Plus Tegafur/Uracil for Patients with Advanced/Metastatic Hepatocellular Carcinoma (Hcc): Final Report
|
徐志宏; 林宗哲; 沈盈君; 許駿; 鄭安理; HSU, CHIH-HUNG; LIN, ZONG-ZHE; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity- Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy
|
許峰銘; 李元麒; 李章銘; 徐志宏; 林家齊; 蔡育傑; 吳簡坤; 成佳憲; HSU, FENG-MING; LEE, YUNG-CHIE; LEE, JANG-MING; HSU, CHIH-HUNG; LIN, CHIA-CHI; TSAI, YU-CHIEH; WU, JIAN-KUEN; CHENG, JASON CHIA-HSIEN |
| 國立臺灣大學 |
2009 |
Disseminated Peritoneal Leiomyomatosis Responds to Systemic Chemotherapy
|
林育靖; 魏凌鴻; 孫家棟; 鄭安理; 徐志宏; LIN, YU-CHIN; WEI, LIN-HUNG; SHUN, CHIA-TUNG; CHENG, ANN-LII; HSU, CHIH-HUNG |
| 國立臺灣大學 |
2009 |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
林家齊; 徐志宏; 成佳憲; 黃昭淵; 蔡育傑; 許峰銘; 黃國皓; 鄭安理; 蒲永孝; LIN, CHIA-CHI; HSU, CHIH-HUNG; CHENG, JASON CHIA- HSIEN; HUANG, CHAO-YUAN; TSAI, YU-CHIEH; HSU, FENG -MING; HUANG, KUO-HOW; CHENG, ANN-LII; PU, YEONG- SHIAU |
| 國立臺灣大學 |
2009 |
Prognostic Factors of Survival in 236 Advanced Hepatocellular Carcinoma Patients Enrolled in Prospective Clinical Trials of Systemic Therapy
|
林宗哲; 邵幼雲; 徐志宏; 許駿; 洪瑞隆; 鄭安理; LIN, ZONG-ZHE; SHAO, YU-YUN; HSU, CHIH-HUNG; HSU, CHIUN; HONG, RUEY-LONG; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Bortezomib Overcomes Trail Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of P13k/Akt Pathway
|
陳昆鋒; 葉培彥; 許駿; 徐志宏; 盧彥伸; 謝興邦; 陳培哲; 鄭安理; CHEN, KUEN-FENG; YEH, PEI-YEN; HSU, CHIUN; HSU, CHIH-HUNG; LU, YEN-SHEN; HSIEH, HSING-PANG; CHEN, PEI-JER; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway
|
陳昆鋒; 葉培彥; 許駿; 徐志宏; 盧彥伸; 謝興邦; 陳培哲; 鄭安理; CHEN, KUEN-FENG; YEH, PEI-YEN; HSU, CHIUN; HSU, CHIH-HUNG; LU, YEN-SHEN; HSIEH, HSING-PANG; CHEN, PEI-JER; CHENG, ANN-LII |
顯示項目 106-115 / 174 (共18頁)
<< < 6 7 8 9 10 11 12 13 14 15 > >>
每頁顯示[10|25|50]項目
|
